Status:

COMPLETED

Clinical Investigation of the Multifocal IOL POD F GF in Cataracteous Eyes

Lead Sponsor:

Beaver-Visitec International, Inc.

Conditions:

Cataract

Lens Opacities

Eligibility:

All Genders

20+ years

Phase:

NA

Brief Summary

To evaluate effectiveness and safety of the POD F GF Intraocular Lens (IOL) when implanted to replace the natural lens following cataract removal

Detailed Description

Since the investigational lens, like conventional IOLs, is a posterior chamber lens which is widely implanted following cataract extraction, phacoemulsification is adopted. To assess the binocular vis...

Eligibility Criteria

Inclusion

  • Adults, 20 years of age or older at the time of informed consent, of either gender, diagnosed with bilateral cataracts;
  • Able to comprehend and sign a statement of informed consent;
  • Willing and able to complete all required postoperative visits;
  • Calculated lens power within the available range;
  • Planned cataract removal by phacoemulsification;
  • Potential postoperative BCDVA of 0.5 decimal or better in both eyes;
  • Subject with preoperative astigmatism \< 1.0 D
  • Clear intraocular media other than cataract in both eyes;
  • The subject must be able to undergo second eye surgery within 30 days of the first eye surgery.
  • \[Justification for the inclusion criteria\]
  • and 5: Cataract extraction is the indication of the clinical study.
  • and 3: One of GCP requirements 4: Essential condition for implant of the investigational lens. 6, 7, 8 and 9: Conditions to minimize the potential non-IOL factors which may affect the visual acuity data

Exclusion

  • \[Exclusion Criteria Prior to Surgery\] The patient who meets any criteria specified in the following 1) through 22).
  • Irregular corneal aberration that affects postoperative visual function as demonstrated by corneal topography;
  • Inflammation or edema (swelling) of the cornea affecting post-operative visual acuity;
  • Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.5 decimal for BCDVA;
  • Subjects who may be expected to require ocular surgery (other than blepharo-surgery, laser surgery of fundus and YAG capsulotomy) during the study;
  • Previous refractive surgery;
  • Amblyopia;
  • Clinically severe corneal dystrophy (eg., epithelial, stromal, or endothelial dystrophy), keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or kerectasia;
  • Diabetic retinopathy;
  • Extremely shallow anterior chamber, not due to swollen cataract;
  • Microphthalmos;
  • Current or previous retinal detachment;
  • Previous corneal transplant;
  • Recurrent severe anterior or posterior segment inflammation of unknown etiology;
  • Rubella or traumatic cataract;
  • Iris neovascularization;
  • Glaucoma or ocular hypertension;
  • Aniridia;
  • Optic nerve atrophy;
  • Planned clear lensectomy (no lens opacity)
  • Pregnancy, lactating or possible pregnant;
  • Participation in any clinical study (drug or device) within 3 months prior to participating this study, planned participation another clinical study during this study, or currently participating in another study.
  • Disqualified by the investigator or the sub-investigator because of physical or ophthalmic diseases.
  • \[Exclusion Criteria During Surgery\] The patient who meets any criteria specified in the following 1) through 7).
  • Mechanical or surgical manipulation required to enlarge the pupil;
  • Excessive iris mobility;
  • Significant vitreous loss;
  • Significant anterior chamber hyphema;
  • Uncontrollable intraocular pressure;
  • Zonular or capsular rupture or tear;
  • IOL could not be fixed in the lens capsule;

Key Trial Info

Start Date :

November 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 30 2021

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT04699266

Start Date

November 1 2020

End Date

August 30 2021

Last Update

August 1 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Miyata Eye Hospital

Miyata, Japan